InaVac gets emergency approval from BPOM

Surabaya, East Java, Indonesia, Nov 14, 2022 – (ACN Newswire via SEAPRWire.com) – The Food and Drug Supervisory Agency (BPOM) has issued emergency use authorization (EUA) for InaVac, a COVID-19 vaccine developed by researchers from Airlangga University (Unair). InaVac, COVID-19 vaccine, is developed by the University of Airlangga in Surabaya, East Java Province. (ANTARA/HO-BPBRIN Unair) […]

AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share

HONG KONG, Oct 5, 2022 – (ACN Newswire via SEAPRWire.com) – AIM Vaccine Co., Ltd. (“AIM Vaccine” or the “Company”, together with its subsidiaries, the “Group”, stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), today announced the allotment results of its Global […]

Bio Farma secures multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)

BANDUNG, INDONESIA, Oct 2, 2022 – (ACN Newswire via SEAPRWire.com) – PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children’s Fund (UNICEF) for 2022 & 23. Under the contract, Bio Farma will […]

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

HONG KONG, Sep 23, 2022 – (ACN Newswire via SEAPRWire.com) – AIM Vaccine Co., Ltd. (“AIM Vaccine” or the “Company”, together with its subsidiaries, the “Group”, stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), announced the proposed listing of its H shares […]

Indonesia’s Bio Farma ready to produce ‘IndoVac’ Covid-19 vaccines

BANDUNG, INDONESIA, Sep 12, 2022 – (ACN Newswire via SEAPRWire.com) – PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in manufacturing IndoVac, its Covid-19 vaccines brand, including primary series vaccines, booster vaccines and vaccines for children, in development since November 2021. IndoVac Covid-19 vaccine in production at […]

Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines

Bandung, W Java, Indonesia, Sep 9, 2022 – (ACN Newswire via SEAPRWire.com) – PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing of IndoVac, a Covid-19 vaccine brand it has developed since November 2021. IndoVac Covid-19 vaccine in production at PT Bio Farma’s facilities near […]

Indonesia approves Pfizer’s booster shot for ages 16 & above

A health worker takes the body temperature of an elderly man before a booster shot of Pfizer COVID-19 vaccine during a third dose vaccination campaign at South Tangerang Regional General Hospital in Tangerang, Indonesia on Jan 24, 2022. (TATAN SYUFLANA / AP) JAKARTA / SINGAPORE / MANILA / HANOI / ISLAMABAD – Indonesia's food and drug authority BPOM has […]

Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years

Cambridge, MA, Jul 19, 2022 – (ACN Newswire via SEAPRWire.com) – Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna’s mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 ug per […]

Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea

SEOUL, S.KOREA, Jul 13, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, congratulates its client SK bioscience on the recent COVID-19 vaccine licence approval. SK bioscience and GSK recently announced the successful authorization: SK bioscience announced that ‘SKYCovione(TM),’ South […]

Legend Capital’s Portfolio Company Recbio Lists on HKEX Successfully

HONG KONG, Apr 7, 2022 – (ACN Newswire via SEAPRWire.com) – On 31 March 2022, Legend Capital’s portfolio company Jiangsu Recbio Technology Co., Ltd. (“Recbio”, stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange. The listing makes Recbio “the first HPV vaccine stock in Hong Kong” and “the […]

Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology

HONG KONG, Apr 1, 2022 – (ACN Newswire via SEAPRWire.com) – On March 31, the China-based novel vaccines company – Jiangsu Recbio Technology Co., Ltd. (“Recbio” or the “Company”, Stock Code: 2179.HK) went public and was officially listed on the Hong Kong Stock Exchange. Assuming the Over-allotment option is not exercised, 30,854,500 H shares were […]

Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Mar 21, 2022 – (ACN Newswire via SEAPRWire.com) – The China-based novel vaccines company – Jiangsu Recbio Technology Co., Ltd. (“Recbio” or the “Company”, stock code: 2179.HK, today announced the proposed listing of its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”). […]

V-01 as a Sequential Booster Can Produce Good Protection against Omicron —- Latest Phase III Data of COVID-19 Vaccine by Livzon Pharma

HONG KONG, Feb 18, 2022 – (ACN Newswire via SEAPRWire.com) – Global pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19. Following the Delta and Beta variants, Omicron variant emerged at the end of 2021, and its enhanced infectivity has cast a shadow over the global […]